Who Fits Semaglutide Heart Criteria?

A 2026 registry analysis estimated that 54.3% of 12,430 people in two cardiology prevention registries theoretically met trial-aligned criteria for semaglutide. That is a planning estimate, not a finding that half of cardiology patients should receive the medicine. The analysis mapped real-world records to criteria linked to SELECT for people without diabetes and SOUL for people with type 2 diabetes.^[1] Our semaglutide overview explains the medicine and its approved presentations.

What the registry study did

Researchers used the START and BRING-UP prevention registries to identify people whose recorded characteristics resembled participants in SELECT or SOUL. They began with 12,430 patients. They excluded 623 because of severe renal impairment or current GLP-1 receptor agonist therapy, leaving 11,807 people for the main classification: 8,682 without diabetes and 3,125 with diabetes.^[1]

Among those without diabetes, 3,689 people, or 42.5%, were classified as SELECT-like. The paper defined that group as people with overweight or obesity and established coronary disease. Among those with diabetes, 3,059 people, or 97.9%, were classified as SOUL-like, using an age threshold of at least 50 years plus cardiovascular disease. Across the original registry population, 6,748 people met one of those theoretical profiles.^[1]

This was not a randomized treatment study. No registry participant was assigned semaglutide or placebo for this analysis, and the paper did not estimate how many would accept treatment, tolerate it, obtain coverage, or remain on it. The useful output is a service-planning denominator: how large the potentially relevant population might be if trial and label criteria are applied to routine cardiology records.^[1]

That denominator can inform a health system's first estimate of screening workload, but it is not a forecast of prescriptions. Each later step can reduce the count: confirming the full trial criteria, matching the correct product label, reviewing contraindications and competing therapies, and discussing preferences with the patient. The registry paper measures the top of that funnel rather than its final treated population.

The SELECT side of the estimate

SELECT was a randomized, double-blind trial of 17,604 adults aged 45 years or older who had preexisting cardiovascular disease, a body-mass index of at least 27, and no diabetes. The primary endpoint combined cardiovascular death, nonfatal heart attack, and nonfatal stroke. An event occurred in 6.5% of participants assigned semaglutide and 8.0% assigned placebo, corresponding to a hazard ratio of 0.80.^[2]

The current US Wegovy label reflects that evidence. It indicates Wegovy injection, alongside reduced-calorie diet and increased physical activity, to reduce major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.^[4] That wording describes a specific approved use, not a blanket cardiovascular indication for everyone. The US semaglutide regulation page keeps the product and jurisdiction visible.

The SOUL side of the estimate

SOUL enrolled 9,650 adults aged 50 years or older with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both. Participants received oral semaglutide or placebo in addition to standard care. Major cardiovascular events occurred in 12.0% of the oral semaglutide group and 13.8% of the placebo group, with a hazard ratio of 0.86. Confirmatory secondary kidney outcomes did not differ significantly between groups.^[3]

The US oral semaglutide label is broader in wording than the registry paper's simplified SOUL-like definition. It indicates Rybelsus and Ozempic tablets to reduce major cardiovascular events in adults with type 2 diabetes who are at high risk for those events.^[5] A registry flag cannot perform the clinical work behind "high risk." Readers can compare product background on the semaglutide evidence page and check country-specific status through the regulation hub.

Why theoretical eligibility is not a prescription

The new paper uses "potentially eligible" carefully. A trial-like profile is one filter. A real decision also has to consider the exact authorised product, contraindications, kidney function, current medicines, adverse-event risk, patient preference, and access. The analysis itself excluded people with severe renal impairment or ongoing GLP-1 receptor agonist therapy, showing how quickly the headline population narrows when basic clinical context is applied.^[1]

Trial populations are also not interchangeable. SELECT studied injected semaglutide in people with overweight or obesity, established cardiovascular disease, and no diabetes.^[2] SOUL studied oral semaglutide in people with type 2 diabetes plus atherosclerotic cardiovascular disease, chronic kidney disease, or both.^[3] The registry study combined those evidence paths for a workforce and budget question. It did not erase their differences.^[1]

Formulation matters for the same reason. Our semaglutide medicine guide distinguishes oral and injectable products, while the UK semaglutide page and US semaglutide page track separate regulatory decisions. A molecule-level headline cannot substitute for the label attached to the actual product in the actual country.^[4][5]

What we do not know yet

The registry analysis does not tell us how many theoretically eligible patients would benefit in routine care, because it did not treat or follow them under a new semaglutide strategy. It does not supply a budget-impact figure, a staffing model, or a comparison against other secondary-prevention options. It also cannot show whether the START and BRING-UP populations represent every health system.^[1]

The analysis also cannot resolve implementation trade-offs. A clinic would still need to decide who confirms eligibility, how adverse effects are monitored, and how follow-up is coordinated with diabetes or weight-management care. Those operational questions matter because a large theoretical pool may translate into substantial assessment work even when only a smaller group proceeds to treatment.

What it does show is scale. Cardiologists may encounter many people whose records resemble the populations behind the cardiovascular semaglutide evidence. That makes careful identification and shared decision-making relevant, but it also raises practical questions about screening, cost, follow-up, and equitable access. Readers looking beyond the headline can start with the semaglutide safety section and the US product-status guide.^[1]